Closed eye care collaboration agreement with AbbVie to develop and commercialize RGX-314
Continue to advance RGX-314 program for the treatment of wet AMD and diabetic retinopathy
Received IND clearance and Orphan Drug Designation for RGX-202 for the treatment of Duchenne
Presented positive data from RGX-121 and RGX-111 clinical trials for the treatment of MPS II and MPS I
$849 million current cash and cash equivalents of as of December 31, 2021; including upfront payment from closing of the AbbVie eye care collaboration agreement; operational runway into 2025
Conference call Tuesday, March 1st at 4:30 p.m. ET
Financial Guidance
Based on its current operating plan, REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $849.3 million as of December 31, 2021 to fund its operations, including the completion of its internal manufacturing capabilities and clinical advancement of its product candidates, into 2025.
Conference Call
In connection with this announcement, REGENXBIO will host a conference call and webcast today at 4:30 p.m. ET. To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 7635958. To access a live or recorded webcast of the call, please visit the "Investors" section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
https://finance.yahoo.com/news/regenxbio-reports-fourth-quarter-full-210500073.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.